Compare JZXN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | SBFM |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 6.0M |
| IPO Year | 2020 | N/A |
| Metric | JZXN | SBFM |
|---|---|---|
| Price | $0.88 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 272.6K | 31.0K |
| Earning Date | 02-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.00 |
| 52 Week High | $8.50 | $2.43 |
| Indicator | JZXN | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 42.78 |
| Support Level | $0.82 | N/A |
| Resistance Level | $1.15 | $1.52 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.51 | 26.77 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It is into trade business with a focus on sales of new energy batteries including design, commissioned processing, transportation and packaging, sales of electrical equipment, mobile phone accessories and other products. Its revenues consist of two reportable operating segments: (i) Sales of new energy batteries, including production, transportation, and packaging, in the mainland Pearl River Delta region; and(ii) Sales and production of electric vehicles in Southeast Asia, including two-wheelers, three-wheeled electric scooters, and slow-speed vehicles.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.